A share price of Eton Pharmaceuticals Inc [ETON] is currently trading at $16.7, down -2.45%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The ETON shares have gain 9.44% over the last week, with a monthly amount glided 20.23%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Eton Pharmaceuticals Inc [NASDAQ: ETON] stock has seen the most recent analyst activity on January 23, 2025, when H.C. Wainwright reiterated its Buy rating and also boosted its price target to $33 from $17. Previously, B. Riley Securities started tracking the stock with Buy rating on January 10, 2025, and set its price target to $21. On January 06, 2025, H.C. Wainwright reiterated its Buy rating and revised its price target to $17 on the stock. Craig Hallum initiated its recommendation with a Buy and recommended $8 as its price target on May 06, 2024. In a note dated January 04, 2021, H.C. Wainwright reiterated an Buy rating on this stock and revised its target price from $20 to $15.
Eton Pharmaceuticals Inc experienced fluctuations in its stock price throughout the past year between $3.75 and $21.48. Currently, Wall Street analysts expect the stock to reach $35 within the next 12 months. Eton Pharmaceuticals Inc [NASDAQ: ETON] shares were valued at $16.7 at the most recent close of the market. An investor can expect a potential return of 109.58% based on the average ETON price forecast.
Analyzing the ETON fundamentals
Trailing Twelve Months sales for Eton Pharmaceuticals Inc [NASDAQ:ETON] were 58.18M which represents 108.60% growth. Gross Profit Margin for this corporation currently stands at 0.59% with Operating Profit Margin at -0.01%, Pretax Profit Margin comes in at -0.07%, and Net Profit Margin reading is -0.07%. To continue investigating profitability, this company’s Return on Assets is posted at -0.04, Equity is -0.19 and Total Capital is -0.01. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.14.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 16.39 points at the first support level, and at 16.09 for the second support level. However, for the 1st resistance point, the stock is sitting at 17.20, and for the 2nd resistance point, it is at 17.71.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Eton Pharmaceuticals Inc [NASDAQ:ETON] is 1.77. In addition, the Quick Ratio stands at 1.16 and the Cash Ratio stands at 0.66. Considering the valuation of this stock, the price to sales ratio is 7.70, the price to book ratio is 18.69.
Transactions by insiders
Recent insider trading involved Krempa David, Chief Business Officer, that happened on Jun 12 ’25 when 16977.0 shares were sold. Chief Business Officer, Krempa David completed a deal on Jun 16 ’25 to sell 10223.0 shares. Meanwhile, Chief Business Officer Krempa David sold 6800.0 shares on Jun 13 ’25.
